{"id":"W2511420668","doi":"10.1016/j.atherosclerosis.2016.08.043","title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","year":2016,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Statin; Medicine; Randomized controlled trial; Internal medicine; Pharmacology; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001588125,0.001808243,0.004078626,0.0003870423,0.0004285556,0.001419549,0.0008789352,0.001440385,0.009839602],"category_scores_gemma":[0.00196548,0.0006892144,0.002800715,0.0003828727,0.00110647,0.001208156,0.0005940628,0.003768452,0.001212467],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009407108,"about_ca_system_score_gemma":0.001149303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001711183,"about_ca_topic_score_gemma":0.004022862,"domain_scores_codex":[0.9994726,0.000239146,0.00003005967,0.0001208142,0.0000329295,0.0001045454],"domain_scores_gemma":[0.9989679,0.0003135411,0.0001859325,0.00007508956,0.00005982627,0.0003978695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9854847,0.001916994,0.0005124909,0.0005489354,0.00150884,0.00002293715,0.00002820782,0.0002061442,0.001173573,0.0001116039,0.001020745,0.007464906],"study_design_scores_gemma":[0.9848949,0.01228787,0.001012412,0.00003096399,0.0009310383,0.00001475449,0.0000176887,0.0001914017,0.000101286,0.0001085728,0.0003975352,0.00001151302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696563,0.01194576,0.0015303,0.002947727,0.00149552,0.003392443,0.003545808,0.000303358,0.005182788],"genre_scores_gemma":[0.973911,0.005438466,0.003270058,0.004349648,0.0008274543,0.003363987,0.002859968,0.00007504921,0.005904342],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009839602,"threshold_uncertainty_score":0.03291672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06538851783828546,"score_gpt":0.3811616000314036,"score_spread":0.3157730821931182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}